Luteinizing Hormone (LH) Supplementation in Gonadotropin-releasing Hormone (GnRH) Antagonist Cycles
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 720
- 试验地点
- 2
- 主要终点
- Implantation rate
研究概览
简要总结
To analyse the impact on cycle outcome of LH supplementation in ovarian stimulation controlled with a GnRH antagonist in two ages groups: patients upto 35 years old, and patients aged between 36 and 39 years old.
详细描述
All patients received an oral contraceptive pill with 0.030 mg of ethinyl-estradiol and 3.0 mg of drospirenone the cycle prior to ovarian stimulation. On the second day of menstruation, patients started ovarian stimulation as follows:
Patients < 36: 225 IU/day of recombinant FSH (FSH alone group) or 150 IU of rFSH and 75 IU of rLH/day (FSH+LH group) for 5 days. On day 6, a 0.25 mg/day dose of the GnRH antagonist Cetrorelix is added until the day of rCG administration.
Patients 36-39: Initial dose of 300 IU of rFSH /day (FSH alone group)) or 225 IU of rFSH and 75 IU of rLH/day (FSH + LH group) for 5 days. On day 6, a 0.25 mg/day dose of the GnRH antagonist Cetrorelix is added until the day of rCG administration.
A maximum of 3 embryos were transferred on day 3 of embryo development.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 39 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •1st-2nd IVF cycle.
- •Age until 39 years old
- •BMI: 18-29.
- •Basal FSH < 12 IU/L
排除标准
- •LH:FSH > 2 (PCO)
- •Low response background (< 5 oocytes)
- •Endometrioma
- •Recurrent pregnancy loss
- •Any preimplantational genetic diagnosis indication
- •Any systemic, metabolic or endocrinological disorder.
结局指标
主要结局
Implantation rate
时间窗: 4 weeks after embryo transfer
次要结局
未报告次要终点